Brands

Willow Biosciences Reports Q3 2024

LOS ANGELES- Willow Biosciences Inc., a biotechnology firm specializing in the industrial production of functional ingredients, has reported its financial results for the third quarter of 2024. The company achieved record revenue of $1.7 million during this period, marking a significant increase from the $674,000 reported in the same quarter of 2023. Despite this revenue ...

November 22nd, 2024|

Medicinal Cannabis Companies Target Veterans with Social Media Promotions, Raising Ethical Concerns

LOS ANGELES- Recent reports indicate that medicinal cannabis companies are increasingly targeting veterans through social media platforms, promoting free products and subscription services. This marketing strategy aims to attract veterans by offering complimentary samples and ongoing product deliveries, leveraging social media's extensive reach to engage this demographic. Advocates argue that such promotions provide veterans with ...

November 12th, 2024|

Urbana Breathes New Life into Historic Luka’s Taproom with a New Cannabis Dispensary and Lounge in Oakland

Honoring a Beloved Oakland Landmark, Urbana Introduces a New Paradigm in Cannabis Retail and Consumption OAKLAND, CA – Urbana, one of Northern California’s premier cannabis brands, is thrilled to announce the opening of its newest dispensary and consumption lounge in the heart of Oakland. Located in the historic Luka’s Taproom, Urbana’s newest site pays tribute ...

September 16th, 2024|

BudLabs: The App Innovating How Cannabis Cultivators Measure Their Success

LOS ANGELES — In cannabis cultivation, staying ahead of the curve requires not only the best products but also the best tools. Advanced Nutrients has taken a significant step in this direction with the development of BudLabs, an innovative mobile app designed to streamline the cultivation process and help growers achieve superior results. BudLabs: Your ...

September 24th, 2024|

Emerald Cup Unites with Local Oakland Dispensary Lounge Urbana for 20th Anniversary Celebrating Legacy and Community

OAKLAND — As the Emerald Cup marks its 20th anniversary this year, the event continues to evolve while staying true to its roots. Often hailed as the "Academy Awards of Cannabis," the Emerald Cup is celebrated for its commitment to honoring the best in cannabis while fostering a strong sense of community.  Seeking a local ...

August 13th, 2024|

Advanced Nutrients Honored with International Cannabis Award for Best Fertilizer USA 2024

LOS ANGELES — Advanced Nutrients continues to lead the cannabis cultivation market, garnering the International Cannabis Award for Best Fertilizer USA 2024. This recognition underscores the company's longstanding commitment to innovation and excellence in cannabis cultivation. In a notable achievement coinciding with their presence at the International Cannabis Business Conference (ICBC) in Barcelona, Advanced Nutrients ...

August 9th, 2024|

Mary Jane Berlin 2024: Epicenter of European Cannabis Culture and Innovation

BERLIN—This week, Berlin is hosting one of the most anticipated events in the cannabis industry: Mary Jane Berlin. From June 14 to June 16, the sprawling Arena Berlin will transform into a vibrant hub for cannabis enthusiasts, industry professionals, and curious visitors alike. This annual event, now a staple in the European cannabis calendar, promises ...

June 12th, 2024|

High Tide Acquires Premium Cannabis Brand Queen of Bud

LOS ANGELES- In a strategic move High Tide Inc. has officially completed its acquisition of the esteemed Queen of Bud brand, including its intellectual property, trademarks, and other valuable assets. This acquisition, announced on March 15, 2024, marks a significant expansion of High Tide's impressive portfolio of consumer-facing brands, such as NuLeaf Naturals, FAB CBD, ...

March 28th, 2024|

Optimi Health Corp. Expands Its Global Reach with MDMA Supply Agreement to Israeli Research Institute

LOS ANGELES – In a landmark move for psychedelic medicine, Optimi Health Corp., a preeminent manufacturer of psychedelics licensed by Health Canada, has announced a groundbreaking international supply agreement with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). This partnership marks Optimi's inaugural foray into the Israeli market, establishing a significant milestone in ...

March 28th, 2024|

Numinus Wellness Secures $6 Million in Public Offering to Fuel Psychedelic-Assisted Therapy Initiatives

LOS ANGELES- Numinus Wellness, a Vancouver-based healthcare company specializing in the innovative field of psychedelic-assisted therapies, has announced the successful completion of a significant financial milestone. Through a "bought deal" public offering, the company has raised $6 million, a move that positions it strongly within the burgeoning sector of mental health care. Financial Details and ...

February 22nd, 2024|

FSD Pharma Announces Market Offering Agreement to Fund Research and Development

NEW YORK- FSD Pharma a biopharmaceutical company focused on developing a diverse portfolio of innovative assets and biotechnological solutions, has unveiled a strategic market offering agreement with H.C. Wainwright & Co. LLC. This collaborative effort paves the way for FSD Pharma to potentially offer and sell up to $11,154,232 in Class B subordinate voting shares ...

February 21st, 2024|

Clearmind Medicine Inc. Advances Psychedelic Therapeutics with New Patent Applications

NEW YORK– Clearmind Medicine Inc. a biotech firm dedicated to the discovery and development of novel psychedelic-derived therapeutics, has taken significant steps to enhance its intellectual property (IP) portfolio through the submission of three patent applications under the international Patent Cooperation Treaty (PCT). This strategic move, in collaboration with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage ...

February 20th, 2024|

MindBio Therapeutics Announces Completion of Groundbreaking Phase 2a LSD Microdose Trial

LOS ANGELES- In a significant advancement for psychiatric medicine, MindBio Therapeutics Corp., a pioneering biopharmaceutical company, has announced the successful completion of its Phase 2a clinical trial, marking a pivotal moment in the development of treatments for Major Depressive Disorder (MDD). This trial is notably the world's first to receive regulatory approval for the take-home ...

February 18th, 2024|

Silo Pharma Advances in Ketamine-Based Treatment for Chronic Pain

LOS ANGELES— In a significant stride toward innovative treatment for chronic pain conditions, Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company in its developmental stage, announced promising developments in its ketamine implant, SP-26. The company, known for its work on novel formulations and drug delivery systems for both traditional therapeutics and psychedelic treatments, is targeting ...

February 15th, 2024|

PharmaDrug Inc. Completes Private Placement to Bolster Corporate Initiatives

LOS ANGELES- a specialty pharmaceutical company, announce the successful completion of its previously disclosed non-brokered private placement, raising total gross proceeds of $326,000. In this offering, the company issued 6,520,000 units at a purchase price of $0.05 per unit, resulting in aggregate gross proceeds of up to $326,000. Each unit consists of one common share ...

February 13th, 2024|

Canopy Growth Reports Fiscal Q3 Earnings Amidst Strategic Shifts and Financial Hurdles

LOS ANGELES- Canopy Growth Corporation, reported a 7% decline in net revenue, amounting to $78.5 million for the fiscal third quarter ending December 31, 2023. The Smiths Falls, Ontario-based company revealed these figures in its latest earnings report, providing a mixed picture of its financial health and operational dynamics. All financial figures are reported in ...

February 9th, 2024|

Clearmind Medicine Secures Patent in China

LOS ANGELES- In a significant advancement for the field of psychedelic-derived therapeutics, Clearmind Medicine, a biotechnology firm with operations in Tel Aviv, Israel, and Vancouver, Canada, has been granted a patent in China for a novel treatment targeting binge behaviors. The treatment is based on a specific chemical compound known as a primary amine aminoindan, ...

February 7th, 2024|

Planet 13 Expands into Florida with Strategic Acquisition of VidaCann

LOS ANGELES- In a bold move aimed at broadening its footprint in the burgeoning U.S. cannabis market, Planet 13 has announced its acquisition of VidaCann, a significant player in the Florida cannabis sector. This all-stock transaction marks a pivotal moment for the Las Vegas-based company, allowing it to leverage VidaCann's established presence—including 26 retail locations ...

February 5th, 2024|

Psyence Biomedical Merges with Newcourt, Listing and Raising US$10 Million for Clinical Trials

LOS ANGELES- Psyence Biomedical Ltd. a subsidiary of Psyence Group Inc, has successfully completed a merger with Newcourt Acquisition Corp (“Newcourt”), a special purpose acquisition company. This business combination, which received approval from Newcourt’s stockholders on January 18, 2024, will introduce Psyence Biomed to the NASDAQ stock exchange under the new ticker symbols “PBM” for ...

January 28th, 2024|

PharmAla Launches “MDXXF” Ticker Amid MDMA Research

LOS ANGELES- PharmAla Biotech Holdings Inc., a biotechnology company specializing in the research, development, and manufacturing of novel MDMA derivatives (MDXX class molecules), has announced the introduction of its new OTC ticker symbol, "MDXXF." This change, effective from January 24th, signifies a strategic alignment with the company's core business focus. The announcement was made by ...

January 25th, 2024|

Incannex Healthcare Concludes Phase 2 Trial of Psilocybin Therapy for Anxiety Disorder, Awaiting FDA IND Application

LOS ANGELES- Incannex Healthcare Inc., a pharmaceutical company in the development of medicinal cannabinoid and psychedelic medicine therapies, has recently completed a significant milestone in its PsiGAD-1 clinical trial. This Phase 2 study, focused on evaluating the company’s proprietary psilocybin treatment for generalized anxiety disorder (GAD), successfully completed dosing and treatment protocols for all 72 ...

January 22nd, 2024|

Irwin Naturals Inc. Reports Financial Performance in Q3 2023

LOS ANGELES- Irwin Naturals Inc, a key player in the cannabis and mental health sectors, recently disclosed its financial results for the third quarter of fiscal 2023, ending September 30, 2023. The report presents a complex picture of the company's financial health and strategic maneuvers in a rapidly evolving market. Financial Highlights for Q3 2023: Q3 ...

November 28th, 2023|

Building a Robust Brand: A Blueprint for Success in the Cannabis Industry

LOS ANGELES-- In a rapidly evolving market, cannabis companies are urged to adopt a nuanced approach to brand building, harmonizing seasoned cannabis expertise with established business principles to foster growth and sustainability. Steve Goldner, a leading branding expert in cannabis, writing here exclusively for Highly Capitalized, Goldner emphasizes the necessity of a well-rounded brand strategy ...

September 11th, 2023|

Cannabis Industry’s Branding Challenge: Beyond Packaging and Social Media

LOS ANGELES–Amid the flourishing cannabis industry, branding efforts often focus on packaging and social media, missing out on essential elements. Experts suggest that cannabis marketing needs to evolve beyond these basics to truly succeed. Cannabis companies must adopt Consumer Packaged Goods (CPG) methods like consumer insights to position and price their brands effectively. The transformative ...

August 12th, 2023|
Go to Top